Warning Letter — Skytron, LLC
The FDA issued a Warning Letter to Skytron, LLC on May 19, 2026, following an evaluation by the Center for Devices and Radiological Health.
This affects Skytron, LLC and its internal departments responsible for regulatory compliance, quality assurance, and manufacturing of medical devices and radiological products.
A Warning Letter from the CDRH indicates that the manufacturer's quality or regulatory controls failed to meet established legal standards. This necessitates immediate corrective action to avoid further enforcement measures, such as seizures or injunctions. The specific nature of the violations is not detailed in the source excerpt, but such letters generally point to significant deviations from Quality System Regulations or premarket requirements.
Quality and regulatory teams should review existing manufacturing and quality management systems for adherence to FDA requirements. Internal audits should focus on documenting corrective actions and ensuring all compliance protocols are followed consistent with CDRH expectations.
FDA Warning Letter issued to: Skytron, LLC. 05/19/2026 — Center for Devices and Radiological Health. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/skytron-llc-723950-05192026
Open in openFDA / FDA.gov